###begin article-title 0
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
SOX9 transduction of a human chondrocytic cell line identifies novel genes regulated in primary human chondrocytes and in osteoarthritis
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1</italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32</italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1</italic>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYBPH</italic>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1 </italic>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1</italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX</italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1</italic>
###xml 789 795 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1</italic>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32</italic>
###xml 804 810 804 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 814 820 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1</italic>
###xml 930 935 930 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 1016 1041 1016 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX, APOD, RGC32, CRTL1 </italic>
###xml 1045 1051 1045 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1</italic>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
The transcription factor SOX9 is important in maintaining the chondrocyte phenotype. To identify novel genes regulated by SOX9 we investigated changes in gene expression by microarray analysis following retroviral transduction with SOX9 of a human chondrocytic cell line (SW1353). From the results the expression of a group of genes (SRPX, S100A1, APOD, RGC32, CRTL1, MYBPH, CRLF1 and SPINT1) was evaluated further in human articular chondrocytes (HACs). First, the same genes were investigated in primary cultures of HACs following SOX9 transduction, and four were found to be similarly regulated (SRPX, APOD, CRTL1 and S100A1). Second, during dedifferentiation of HACs by passage in monolayer cell culture, during which the expression of SOX9 progressively decreased, four of the genes (S100A1, RGC32, CRTL1 and SPINT1) also decreased in their expression. Third, in samples of osteoarthritic (OA) cartilage, which had decreased SOX9 expression compared with age-matched controls, there was decreased expression of SRPX, APOD, RGC32, CRTL1 and SPINT1. The results showed that a group of genes identified as being upregulated by SOX9 in the initial SW1353 screen were also regulated in expression in healthy and OA cartilage. Other genes initially identified were differently expressed in isolated OA chondrocytes and their expression was unrelated to changes in SOX9. The results thus identified some genes whose expression appeared to be linked to SOX9 expression in isolated chondrocytes and were also altered during cartilage degeneration in osteoarthritis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 959 960 959 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
The chondrocytes within articular cartilage are responsible for the maintenance of the specialized extracellular matrix (ECM) of the tissue and for its biomechanical properties. The chondrocyte phenotype is characterized by the expression of specific genes, such as collagen type II and the transcription factor SOX9 [1]. Collagen type II is an abundant component in the cartilage ECM and is essential for its integrity. Damage to collagen type II and loss of other cartilage ECM components occur during degenerative joint diseases such as osteoarthritis (OA), which result in severe disability and present a major health problem in the ageing population [2]. This may arise from complex pathogenic mechanisms, which result in decreased matrix synthesis and upregulated pathways of tissue degradation [3]. Characteristic of cartilage in OA are changes in the expression of ECM genes and the downregulation of the key chondrogenic transcription factor SOX9 [4,5].
###end p 4
###begin p 5
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1</italic>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL9A1</italic>
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL11A2</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1</italic>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 647 651 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
A large number of cartilage matrix genes have been shown to come under the transcriptional control of SOX9. They include COL2A1, COL9A1, COL11A2, aggrecan and cartilage link protein (CRTL1) genes [6-9], all of which play important roles in articular cartilage structure and function. Furthermore, SOX9 is expressed in presumptive cartilage during embryo development, and mutations in the human SOX9 gene, which result in haploinsufficiency of SOX9, cause campomelic dysplasia with skeletal malformation and dwarfism [10]. Moreover, mice chimaeras containing both wild-type and SOX9-null cells develop normally, but there is no contribution by the SOX9-null cells towards cartilage formation [11].
###end p 5
###begin p 6
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1 </italic>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1 </italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 974 983 974 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 623 628 <span type="species:ncbi:9606">human</span>
###xml 857 862 <span type="species:ncbi:9606">human</span>
The expression of SOX9 declines rapidly in chondrocytes that are isolated and cultured in monolayer [12], and this is accompanied by a reduction in the expression of cartilage matrix genes such as COL2A1 [13]. Overexpression of SOX9 in human chondrocytes passaged in culture increases COL2A1 expression and increases their capacity to reform a cartilage ECM when placed in chondrogenic culture [14-16]. In view of the importance of SOX9 in the development and maintenance of the chondrocyte phenotype, its down regulation in OA is clearly likely to contribute to cartilage pathology. We investigated SOX9 transduction of a human chondrocytic cell line to identify genes that are differentially expressed in the presence by SOX9. We then investigated the expression of these genes in both cDNA samples representative of normal or OA cartilage and in primary human articular chondrocytes during culture and dedifferentiation to establish whether they were similarly regulated in vitro and in cartilage pathology.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Tissue collection
###end title 8
###begin p 9
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">Patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
Osteoarthritic cartilage was obtained from patients undergoing total knee arthroplasty for clinically and radiologically diagnosed OA [17]. Patients were excluded if there was any history of inflammatory arthropathies, or infection within the knee. Normal articular cartilage was obtained from patients undergoing above-knee amputation who had no history of joint disease. All tissue was obtained with fully informed consent and ethical approval. For tissue culture, cartilage from intact regions of joints with clinical confirmation of degenerative OA was harvested and subject to sequential trypsin/collagenase digestion to isolate chondrocytes as previously described [14]. For gene-expression studies, paired full depth samples were taken from each joint (8 normal joints and 15 OA joints), with one sample being harvested from a major loaded area on the medial femoral condyle (MFC), and one from the less loaded lateral posterior condyle (LPC), placed in RNAlater and transferred to the laboratory on ice.
###end p 9
###begin title 10
Culture and retroviral transduction of cells
###end title 10
###begin p 11
###xml 246 247 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 438 443 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 474 477 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP</italic>
###xml 500 502 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 503 505 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 654 657 648 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP</italic>
###xml 992 994 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1372 1374 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 118 124 <span type="species:ncbi:9913">bovine</span>
###xml 420 425 <span type="species:ncbi:9606">human</span>
###xml 799 803 <span type="species:ncbi:9925">goat</span>
###xml 868 873 <span type="species:ncbi:9606">Human</span>
Monolayer cultures of SW1353 cells were kept in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 100 units/ml penicillin and 100 units/ml streptomycin (all from Cambrex, Wokingham, UK) at 37degreesC, 5% CO2. For retroviral transductions, 40% confluent cultures were infected in standard culture medium with an RKAT retrovirus containing a bicistronically expressed cDNA encoding human FLAG tagged SOX9 and green fluorescent protein (GFP), at a titre of 5 x 106 [14]. After three repeated transductions, more than 90% of the cells were transduced and the cells were designated SOX9-SW1353. Cells transduced with a GFP-only retrovirus were used as controls and designated GFP-SW1353. SOX9 protein was assessed in the cells by immunoblotting using an anti-SOX9 goat polyclonal antibody (H-90, Santa Cruz Biotechnology, Calne UK). Human articular chondrocytes were isolated from cartilage on OA knee joints and maintained in culture in medium (as above) [14]. Cells were harvested for gene-expression analysis within the first week of culture (P0) and after 1 and 2 passages (P1 and P2). HACs were transduced with SOX9 or GFP-only retrovirus at passage 4 after first increasing their proliferation rate by adding platelet derived growth factor BB, transforming growth factor beta1 and fibroblast growth factor 2 to the culture medium [14]. Gene expression in these cells was analysed at passage 6-8.
###end p 11
###begin title 12
Microarray analysis
###end title 12
###begin p 13
###xml 489 492 487 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">16 </sub>
###xml 1406 1411 1376 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10&#8211;20</sub>
###xml 1433 1436 1402 1405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">16 </sub>
###xml 2061 2063 2022 2024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2301 2303 2262 2264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2487 2488 2448 2449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2657 2659 2618 2620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 3019 3021 2980 2982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 27 32 <span type="species:ncbi:9606">Human</span>
###xml 97 102 <span type="species:ncbi:9606">Human</span>
###xml 1373 1378 <span type="species:ncbi:9606">human</span>
Glass spotted microarrays (Human known gene SGC oligo set array number 1) were obtained from the Human Genome Mapping Project. Each glass slide contains 9600 spotted oligonucleotides printed in duplicate, approximately 600 bp in length corresponding to the 3' region of each gene's mRNA. Probes were created from RNA, which was isolated from confluent monolayer cultures of GFP-SW1353 or SOX9-SW1353 using Tri Reagent (Sigma, Poole UK). 50 mug of total RNA was added to 2 mug of oligo d(T)16 (Invitrogen, Paisley, UK) and incubated at 70degreesC for 10 minutes before snap cooling on ice for 2 minutes. RNA was reverse transcribed to produce a cDNA probe in a labelling mix containing 1x first strand synthesis buffer, 500 muM DTT, 500 muM dATP, 500 muM dTTP, 500 muM dGTP, 100 muM dCTP, 400 units of superscript II reverse transcriptase (Invitrogen) and either 100 muM Cy3-dCTP or 100 muM Cy5-dCTP (Amersham, Uxbridge, UK). Labelling reactions were incubated for 2 hours at 42degreesC before adding EDTA to 1 mM to stop the reaction. RNA in the samples was degraded by adding sodium hydroxide to 25 mM and heating at 70degreesC for 10 minutes. Samples were neutralised by addition of hydrochloric acid, and labelled cDNA was purified using a PCR clean up kit (Qiagen, Crawley UK). The purified probe was eluted in 50 mul of nuclease free water and combined with 10 mug of human Cot-1 DNA, 6 mug oligo d(A)10-20, and 3 mug oligo d(T)16 (all from Invitrogen), and the volume reduced to 18 mul by vacuum centrifugation. The probe was then combined with 18 mul of a 2x hybridisation solution (final concentration: 25% formamide, 5 x SSC and 0.1% SDS), boiled for 3 minutes and hybridised overnight at 42degreesC under a glass cover slip. The arrays were then washed for 3 minutes each in 2x SSC, 0.1x SSC/0.1% SDS, and 0.1x SSC. Raw intensities at 635 nm and 532 nm were obtained for analysis from four independently probed arrays using the same starting RNA sample using a GenePix 4000A confocal microarray scanner. This data was imported into MaxDView software [18] and each pair of red/green measurements were subjected to intensity-dependant normalization. This removed intensity-dependent bias introduced by the use of the two different fluorophores as probe labels using the Loess (Lowess) method [19] and converted the data to a log ratio with the mean set to zero following normalisation. Quadruplicate log ratios were averaged and standard deviations were determined. In addition, t-tests were carried out comparing the four replicates to zero to determine potentially significantly regulated genes. Data was filtered to display only those genes with P < 0.05 and greater than twofold change in expression. Raw data from each individual channel of each array was also subjected to principle components analysis (PCA) and hierarchical clustering following normalisation of data (log2, mean set to 0 and standard deviation set to 1) using Partek software. All pre-normalised data has been submitted to MIAMExpress [20] at the European Bioinformatics Institute to allow public access (ArrayExpress Accession number E-MEXP-826).
###end p 13
###begin title 14
RNA extraction and cDNA synthesis
###end title 14
###begin title 15
Cell culture
###end title 15
###begin p 16
Total RNA was prepared from monolayer SW1353 and HAC cultures using Tri Reagent. cDNA was synthesised from 1 mug of total RNA using M-MLV reverse transcriptase and primed with random hexamers oligonucleotides (Promega, Southampton, UK) in a 25 mul reaction.
###end p 16
###begin title 17
Tissue extraction
###end title 17
###begin p 18
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Total RNA from cartilage was obtained by homogenization with Braun mikrodismembrator followed by Trizol extraction and chloroform/ethanol purification. Total RNA was then isolated using RNeasy minicolumns and reagents, according to the manufacturers instructions (Qiagen, Crawley, Surrey, UK) including on-column digestion of residual DNA using a RNase-Free DNAse kit (Qiagen) [21,22]. cDNA was synthesised from 10-100 ng of total RNA using global amplification methodology [23].
###end p 18
###begin title 19
Real time PCR analysis
###end title 19
###begin p 20
###xml 469 479 468 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;CCt </sup>
###xml 487 489 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 513 518 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 520 526 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL1A1</italic>
###xml 528 534 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1</italic>
###xml 546 550 541 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX6</italic>
###xml 556 561 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 597 602 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 657 659 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 831 832 826 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Real time PCR was used to determine the expression of chondrocyte genes identified as being regulated by SOX9 in the microarray experiments. Amplification by PCR was carried out in 25 mul reaction volumes on a MJ Research Opticon 2 using reagents from a SYBR Green Core Kit (Eurogentec, Seraing, Belgium) with gene-specific primers designed using Applied Biosystems Primer Express software. Relative expression levels were normalised to GAPDH and calculated using the 2-DeltaCCt method [24]. Primer sequences for GAPDH, COL1A1, COL2A1, aggrecan, SOX6, and SOX9 for identification of the effect of SOX9 transduction in SW1353 have been described previously [15]. Primer sequences for the other genes of interest were designed with a 3' bias to allow accurate quantification of the globally amplified cartilage cDNA libraries (Table 1).
###end p 20
###begin p 21
Primer sequences used to quantify gene expression
###end p 21
###begin title 22
Database analysis of conserved SOX9 binding regions
###end title 22
###begin p 23
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32 </italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 210 213 <span type="species:ncbi:9615">dog</span>
Candidate gene alignments were visualised using Vista Browser [25]. Conserved SOX9 consensus binding sites, defined by the Transfac database, were identified by comparing the human genome with that of mouse or dog using rVista [26]. SPINT1 and GAPDH genes were analysed in their entirety as well as up to 7 kb upstream of the transcription start site. Due to the very large intron size of the APOD, RGC32 and SRPX genes, only 7 kb upstream of the transcription start site and the regions within the first intron of these genes were included in this analysis. Conserved sites identified in both species comparisons were accepted as potential SOX9 binding regions.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
Unpaired t-tests were used to compare the effect of SOX9 transduction on cultured cells. Statistical analyses to identify the effect of both disease state and site within the joint on gene expression were performed using mixed effects linear regression models following transformation of the data to allow normal distribution.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
Changes in gene expression in SOX9 transduced SW1353 cells
###end title 27
###begin p 28
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 427 431 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 437 440 437 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP</italic>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1030 1035 1030 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX6 </italic>
###xml 1055 1062 1055 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1 </italic>
###xml 1132 1136 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 1180 1187 1180 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL1A1 </italic>
###xml 1261 1266 1261 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX6 </italic>
###xml 1270 1277 1270 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1 </italic>
###xml 1280 1285 1280 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 1475 1480 1475 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 1494 1496 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 582 587 <span type="species:ncbi:9606">human</span>
Retroviral transduction with SOX9 was carried out on a human chondrocytic cell line (SW1353), which had previously been shown to have responses to growth factors and cytokines similar to primary chondrocytes [27] and provided RNA in amounts appropriate for microarray analysis. The SW1353 cells were transduced at ~90% efficiency with a SOX9-GFP bicistronic retroviral vector (SOX9-SW1353), and controls were transduced with a SOX9-free GFP-retrovirus (GFP-SW1353) (Figure 1a). The SW1353 cells were of interest for this study as their normal expression of SOX9 was much lower than human chondrocytes in cartilage (relative to GAPDH), whereas the level of SOX9 expression following transduction was increased by 18-fold (Figure 1c) and approached the level found in cartilage. There was no discernable change in morphology following SOX9 transduction. Immunoblotting confirmed that SOX9-SW1353 synthesised increased levels of the SOX9 protein compared with controls (Figure 1b). The cells also showed increased gene expression of SOX6 (up to 14-fold) and COL2A1 (up to 13-fold), but aggrecan expression was low and was unchanged by SOX9. The SW1353 cells expressed high levels of COL1A1 and this was reduced 6-fold by SOX9 transduction. The stimulation of both SOX6 and COL2A1 by SOX9 confirmed that SW1353 cells were responsive to this factor, unlike other non-chondrocytic cells, such as dermal fibroblasts, which failed to upregulate cartilage matrix genes in response to SOX9 transduction [28].
###end p 28
###begin p 29
###xml 62 65 62 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP </italic>
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9-GFP</italic>
###xml 241 244 240 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 263 266 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP</italic>
###xml 271 275 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 352 355 351 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 459 468 458 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9-GFP </italic>
Retroviral expression of SOX9 in SW1353 chondrosarcoma cells. (a) Phase contrast micrograph demonstrating the morphology of SW1353 chondrosarcoma cells transduced with a retrovirus containing GFP or bicistronic SOX9-GFP. Scale Bar = 50 mum. (b) Cell lysates from GFP- or SOX9-SW1353 cells were analysed by western blotting using an anti-SOX9 antibody. (c) Real time PCR analysis of cDNA derived from green-fluorescent protein (GFP; black bars) or bicistronic SOX9-GFP (grey bars) transduced SW1353 chondrosarcoma cells.
###end p 29
###begin title 30
Microarray analysis of SOX9-transduced SW1353 cells
###end title 30
###begin p 31
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 171 174 171 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 517 518 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Dual hybridisations were performed in quadruplicate (including duplicated orientations of dye to sample) using probes produced from single RNA samples from SOX9-SW1353 or GFP-SW1353 cells. Extensive filtering of the normalised data was carried out as described in the materials and methods section. From the original 9,600 different genes on each array, 22 were found to be upregulated and 9 were downregulated by SOX9. From these, eight of the most strongly regulated genes were selected for further analysis (Table 2).
###end p 31
###begin p 32
Candidate genes chosen following microarray analysis of SOX9 transduced SW1353 chondrosarcoma cells
###end p 32
###begin p 33
Genes demonstrated regulation consistently across quadruplicate microarray experiments. NA, not applicable.
###end p 33
###begin title 34
Real time PCR analysis of SOX9-regulated genes
###end title 34
###begin p 35
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32 </italic>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 366 372 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1</italic>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1 </italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYBPH </italic>
Gene-expression analysis by quantitative real time (qRT) PCR was used to confirm the gene changes identified by the microarray analysis. Statistically significant upregulation was observed for SRPX (1.8-fold), S100A1 (7.9-fold), APOD (4.2-fold) RGC32 (2.3-fold) and CRTL1 (2 fold) with analyses from separately cultured SW1353 cells. Regulation of the expression of SPINT1, CRLF1 and MYBPH could not be confirmed.
###end p 35
###begin p 36
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 392 394 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 405 412 405 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 425 431 425 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 506 513 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 869 875 869 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYBPH </italic>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 696 701 <span type="species:ncbi:9606">human</span>
Having previously shown that retroviral transduction with SOX9 of passaged human OA chondrocytes re-activated their potential to form cartilage matrix [15], we investigated the expression of the novel genes identified in SW1353 cells in human articular chondrocytes that had been expanded in monolayer culture and transduced with SOX9-retrovirus. The results showed significant upregulation (P < 0.05) of S100A1 (26.8-fold), CRTL1 (3.0-fold) and SRPX (1.7-fold) following SOX9 transduction. Interestingly, SPINT1 was also significantly upregulated in the chondrocytes (2.1-fold), which differed from the finding in the SW1353 cells. APOD was expressed at very low level in transduced and control human OA chondrocytes in monolayer culture, and although its expression appeared to be increased slightly following SOX9 transduction, no statistical analysis was possible. MYBPH expression was again unaffected by SOX9. Therefore, there were examples of genes that displayed similar responses to SOX9 transduction in both SW1353 cells and primary chondrocytes, but also genes for which there were clear regulatory differences between the cell types.
###end p 36
###begin title 37
Primary chondrocyte culture with decrease in SOX9 expression
###end title 37
###begin p 38
###xml 149 158 149 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1</italic>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32</italic>
###xml 654 660 654 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 664 671 664 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 762 766 762 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX</italic>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 921 926 921 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1</italic>
###xml 985 991 985 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYBPH </italic>
###xml 995 1000 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 1047 1052 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 1100 1105 <span type="species:ncbi:9606">human</span>
To determine whether the expression of genes identified in this study were altered by non-viral-mediated changes in SOX9 expression, we investigated in vitro cultures of freshly isolated human articular chondrocytes (Figure 2). These cells were from OA cartilage, and had a lower expression of SOX9 in culture than in tissue, but still higher (relative to GAPDH) than in SW1353 cells. During monolayer culture of the OA chondrocytes there was a further 8-10-fold decrease in SOX9 expression, and we examined whether this was accompanied by any change in expression of the newly identified genes (Figure 2). A number of the genes including S100A1, RGC32, CRTL1 and SPINT1 were down regulated under these conditions, and therefore correlated with the reduction in SOX9. SRPX, in contrast, did not correlate with SOX9 in the monolayer cultured HAC, and its expression increased with passage. The expression of another gene, CRLF1, was unchanged during the fall in SOX9. The expression of MYBPH and APOD (one of the genes most strongly upregulated by SOX9 in SW1353 cells) were very low in these primary human articular chondrocytes, and significant regulation could not be identified.
###end p 38
###begin p 39
###xml 393 395 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 133 138 <span type="species:ncbi:9606">human</span>
Regulation of candidate genes during chondrocyte dedifferentiation. Real time PCR analysis of candidate gene expression in cDNA from human articular chondrocytes at passage (P) 0, 1 or 2. Mean fold-change values (where P0 = 1) with standard errors are presented from chondrocytes cultures obtained from 3 donors. * indicates significant difference in expression compared with passage 0 levels P < 0.05 by paired students t-test.
###end p 39
###begin title 40
Expression of SOX9-regulated genes in normal and osteoarthritic cartilage
###end title 40
###begin p 41
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 615 617 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 850 856 850 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 857 859 857 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 868 873 868 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 874 876 874 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 887 894 887 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 895 897 895 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 908 914 908 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32 </italic>
###xml 915 917 915 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 930 935 930 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 936 938 936 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 960 965 960 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1</italic>
###xml 1039 1041 1039 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1054 1061 1054 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 1412 1416 1412 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 1445 1447 1445 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1522 1529 1522 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 1544 1550 1544 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1 </italic>
###xml 1673 1677 1673 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMP</italic>
In a previous study [5] we showed that osteoarthritic cartilage consistently showed reduced expression of SOX9 compared with healthy age-matched control tissue. It was therefore of great interest to understand whether the newly identified genes were also altered in expression in OA cartilage. We therefore probed globally amplified cDNA samples from normal and OA femoral knee cartilage [5] for their expression (Figure 3). Furthermore, the tissues samples analysed were paired cartilage samples from high-load-bearing (MFC) and low-load-bearing regions (LPC) of the same joints. SOX9 gene expression was reduced (P < 0.0001) in the osteoarthritic samples compared with the age-matched controls, and there was no difference between differently loaded sites. Of the genes investigated, five were expressed at lower level in osteoarthritic cartilage (CRTL1 (P < 0.01), SRPX (P < 0.0001), SPINT1 (P < 0.0001), RGC32 (P < 0.001) and APOD (P < 0.0001)). One gene (CRLF1) was significantly upregulated in OA tissue compared with normal tissue (P < 0.01), and S100A1 showed a wide range of expression and no significant difference between OA and controls; however, analysis of the results from all the cartilage samples showed that its expression was correlated with SOX9. Most genes investigated showed similar expression in both the more highly loaded MFC and the lower loaded LPC sites. The exceptions to this were APOD, which was further reduced (P < 0.01) in expression in the more loaded and damaged cartilage, while both S100A1 (p < 0.03) and CRLF1 (p < 0.02) were expressed at higher levels in the more loaded tissue. The analysis of cartilage oligomeric matrix protein (COMP) gene expression showed that it was unaffected in OA (or location in the joint), and demonstrated that there was no generalised downregulation of all gene expression in OA chondrocytes.
###end p 41
###begin p 42
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 243 245 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 577 579 577 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 639 641 639 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 251 256 <span type="species:ncbi:9606">human</span>
Comparison of the expression levels of candidate genes in normal and osteoarthritic cartilage. Real time PCR analysis of candidate gene expression in globally amplified cDNA representative of mRNA levels from normal (n = 8) or osteoarthritic (n = 15) human articular cartilage samples. Cartilage for the analysis was derived from either the medial or lateral femoral condyles. NM = normal medial, NL = normal lateral, OM = osteoarthritic medial and OL = osteoarthritic lateral. Symbols above bars indicate statistically significant regulation of that gene caused by:* disease (P < 0.05 mixed effects regression model) or â—† joint location (P < 0.05 mixed effects regression model).
###end p 42
###begin title 43
Genomic analysis of potential SOX9 binding sites in candidate genes
###end title 43
###begin p 44
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1</italic>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX</italic>
###xml 34 53 34 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD, RGC32, CRTL1 </italic>
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 827 833 827 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 650 655 <span type="species:ncbi:9606">human</span>
###xml 657 662 <span type="species:ncbi:10090">mouse</span>
###xml 667 670 <span type="species:ncbi:9615">dog</span>
The candidate genes SPINT1, SRPX, APOD, RGC32, CRTL1 and S100A1 were among those whose expression followed that of SOX9 in most of the experimental systems that we examined. Of these genes, CRTL1 and S100A1 have previously been shown to possess SOX9 binding sequences within their promoter regions [9,29]. Potential SOX9 binding sites in non-coding, conserved regions of the genome in and around the other four gene loci were studied using rVista. This tool identifies conserved transcription factor binding sites in sequences based on homologies of such sites between different species, and in these genes it identified binding site conservation in human, mouse and dog sequences (Table 3). The analysis demonstrated conserved SOX9 binding regions in all four candidate genes. As a control, analysis of the house-keeping gene GAPDH revealed no potential SOX9 binding sites common to all three genomic sequences.
###end p 44
###begin p 45
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Predicted SOX9 binding sites in candidate genesa
###end p 45
###begin p 46
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aBase pair (bp) positions are given relative to the transcription start site of each gene. In all instances, positive numbers describe sites within the first intron of the gene.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 206 213 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1 </italic>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The transcription factor SOX9 has been shown to control the transcription of a number of important cartilage matrix genes. It is able to interact with a conserved cartilage-specific enhancer element in the COL2A1 gene and can bind to promoter and enhancer regions in a number of other cartilage matrix genes [6-9]. This work has now identified a number of genes whose expression was changed in SW1353 cells by increasing SOX9 expression by retroviral transduction and may similarly contain conserved SOX9 response elements
###end p 48
###begin p 49
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 270 272 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 439 441 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 633 635 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 760 762 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 847 853 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL2A1</italic>
###xml 1175 1177 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human SW1353 cells have previously been used to elucidate cytokine regulation of ECM-degrading proteases as model chondrocytes [27,30] and their SOX9 expression was shown to be increased by fibroblast growth factors 1, 2 and 9 and decreased by IL1beta and TNFalpha [31]. They have also been used to identify cyclic AMP response element binding protein and p300 as novel partners of SOX9 that bind at cartilage-specific promoter sites [32]. Thus the SW1353 cells have some features of chondrocytes, but as with other chondrocytic cells in monolayer culture they expressed low levels of both cartilage ECM genes and SOX9, 6 and 5 [33]. Their transduction of cytokine signals has also been reported to differ from that seen in primary articular chondrocytes [33]. In this study SOX9-transduction increased the expression of target genes (such as COL2A1), although others appeared unaffected (such as aggrecan). The SW1353 cells therefore appear to lack some chondrocyte properties, but their response to SOX9 transduction was clearly more chondrocyte-like than dermal fibroblasts, which showed no regulation cartilage matrix genes in response to the overexpression of SOX9 [28].
###end p 49
###begin p 50
###xml 982 988 982 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1</italic>
###xml 990 995 990 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32</italic>
###xml 997 1003 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 1007 1014 1007 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
From the initial microarray analysis we followed up gene-expression changes by qRT-PCR analysis in SOX9-SW1353 cells to confirm their regulation. Investigation of changes in the expression of this panel of genes in primary human chondrocytes following SOX9 transduction showed that some genes showed evidence of similar control to SW1353 cells, although some showed no comparable response. To extend these observations we investigated the expression in articular chondrocytes under conditions where the expression of SOX9 was changed by both natural and pathological factors. The expression was investigated in primary human chondrocytes cultured and passaged in monolayer, under which conditions the expression of SOX9 progressively becomes reduced. It was only after culture of the OA chondrocytes that the expression of SOX9 became reduced to the level found in the SW1353 cells before transduction. The change in expression during this fall in endogenous SOX9 expression showed S100A1, RGC32, CRTL1 and SPINT1 to decrease, which were therefore correlated with SOX9, as in SW1353 cells.
###end p 50
###begin p 51
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 629 635 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1 </italic>
###xml 636 638 636 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 653 655 653 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 666 673 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINT1 </italic>
###xml 674 676 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 687 693 687 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32 </italic>
###xml 694 696 694 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 709 714 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 715 717 715 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 976 977 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1125 1130 1125 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRTL1</italic>
###xml 1132 1137 1132 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGC32</italic>
###xml 1139 1146 1139 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 1150 1154 1150 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 1306 1311 1306 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 269 274 <span type="species:ncbi:9606">human</span>
The identification of these SOX9-regulated genes led us to probe a human normal and OA cartilage library of globally amplified cDNA representing mRNA levels in chondrocytes in cartilage taken from load bearing or non-load-bearing regions from age-matched normal and OA human knees. SOX9 has been shown to be downregulated in osteoarthritis, and this may contribute to the pathological process by causing a reduction in the expression of ECM genes [4,5]. We found that many of the genes whose expression was altered by SOX9 in SW1353 cells and/or isolated primary chondrocytes displayed altered expression levels in OA cartilage (CRTL1 (P < 0.01), SRPX (P < 0.0001), SPINT1 (P < 0.0001), RGC32 (P < 0.001) and APOD (P < 0.0001)) compared with age-matched controls. It is worth noting that even a gene such as COL2A1, which is known to have SOX9 regulatory elements, has been demonstrated to poorly correlate with the expression of SOX9 in control and osteoarthritic cartilage [4], suggesting that in OA its expression is more dominantly controlled by other factors. It was therefore more interesting to identify genes such as CRTL1, RGC32, S100A1 and APOD, which had a pattern of expression closely correlating with SOX9 expression levels in SW1353 cells, in primary chondrocytes, and also in OA cartilage. SRPX generally correlated with SOX9, except during chondrocyte dedifferentiation, which may indicate that other factors predominantly influence it during this process.
###end p 51
###begin p 52
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 819 825 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTRL1 </italic>
###xml 829 833 829 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9</italic>
###xml 286 291 <span type="species:ncbi:9606">human</span>
APOD, which was expressed at relatively low levels in SW1353 cells, was expressed more strongly in cartilage, and the expression was reduced in OA, which was consistent with the decrease in SOX9. APOD encodes apolipoprotein D, which is a protein component of low density lipoprotein in human plasma [34], and is reported to be a transit protein in the skin [35]. It may therefore have some function in cartilage ECM. The finding that APOD is downregulated in OA agrees with two previous microarray studies comparing normal and OA tissue [36,37]. The present results showed further that APOD expression was not only downregulated in OA, but was also most strongly downregulated in the highly loaded, more physically damaged cartilage. APOD expression thus correlated with cartilage damage, whereas matrix genes, such as CTRL1 and SOX9, were similarly changed in OA in both low-loaded and high-loaded cartilage sites.
###end p 52
###begin p 53
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A1 </italic>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
S100A1 encodes an intercellular calcium-binding protein, which can control myocardial contractility [38] and has recently been identified as an important SOX9 regulated gene that controls the terminal differentiation of chondrocytes [29]. S100A1 has previously been reported to be downregulated in osteoarthritis [36]. In the OA and control cartilage samples investigated here, S100A1 had lower mean expression in OA, but the difference was not statistically significant. However, its expression was found to be significantly correlated with SOX9 when the results from all cartilage samples were analysed (data not shown).
###end p 53
###begin p 54
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRPX </italic>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 974 979 974 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOX9 </italic>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 1018 1023 <span type="species:ncbi:10090">mouse</span>
SRPX expression was increased by SOX9 transduction in SOX9-SW1353 and in primary human articular chondrocytes, and its expression was greatly reduced in OA cartilage. It therefore correlated well with SOX9 expression, although during chondrocyte dedifferentiation its expression increased more than sevenfold by passage 2 and was clearly unrelated to SOX9. This perhaps emphasises that any loss of chondrocyte phenotype in OA cartilage does not occur through a mechanism closely related to the loss of phenotype that occurs in these cells in monolayer culture. SRPX has a recognised role in ocular biology and disease. The SRPX gene encodes a putative membrane protein expressed abundantly in the retina, and was discovered as a candidate gene responsible for X-linked retinitis pigmentosa [39]. SOX9 has a potential regulatory role in the development of the retina, and may regulate the synthesis of collagen type II in the vitreous of the eye [40]. Furthermore, disrupted SOX9 expression in the 'odd sex' transgenic mouse, which results in sex reversal, also causes an eye phenotype with microphthalmia with cataracts [41]. The expression of SRPX may therefore be regulated by SOX9 during ocular development and may also have a role in cartilage biology.
###end p 54
###begin p 55
###xml 617 619 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 620 622 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 779 785 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRLF1 </italic>
Despite being unable to confirm any regulation by SOX9 in SW1353 by real time PCR, and with its expression unaffected in primary chondrocytes by the transition to monolayer culture, it was interesting that CRLF1 was significantly upregulated in osteoarthritic cartilage. CRLF1 protein is a member of the cytokine type I receptor family, and when expressed as a heterodimer with the cardiotrophin-like cytokine (CLC) can activate the membrane bound ciliary neurotrophic factor receptor-alpha (CNTFRalpha), which causes an interaction between gp130 and leukaemia inhibitory factor receptor, leading to cell signalling [42,43]. Further work characterising the expression of the genes encoding CNTFRalpha and CLC in cartilage is required as does the possibility that upregulation of CRLF1 expression could have a use as a marker of OA.
###end p 55
###begin p 56
This study identified genes whose expression in chondrocytes was consistently correlated with changes in SOX9 expression. The results suggested that the expression of these genes may be regulated by SOX9, and as SOX9 is essential for chondrocyte phenotype, the novel genes with unknown function may help control the differentiated state of chondrocytes within cartilage. The correlation of expression with SOX9 linked these genes to changes in cartilage in OA. As OA is characterized by degenerative changes in cartilage it will be important to establish how the changes in the expression of SOX9-regulated genes contribute to the progressive loss of chondrocyte function and the compromise in cartilage integrity that occurs in OA.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 214 219 <span type="species:ncbi:9606">human</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
We have identified genes in a human chondrosarcoma cell line whose expression is altered by the overexpression of the chondrogenic transcription factor SOX9. Some of these genes were similarly regulated in primary human chondrocytes in response to changes in SOX9 induced by overexpression or by dedifferentiation in culture. The expression of some of these genes was also correlated with SOX9 expression in intact human articular cartilage, and was therefore suppressed in OA cartilage compared with age-matched control cartilage.
###end p 58
###begin title 59
Abbreviations
###end title 59
###begin p 60
###xml 165 171 <span type="species:ncbi:9913">bovine</span>
CLC = cardiotrophin-like cytokine; CNTFR = ciliary neurotrophic factor receptor; DMEM = Dulbecco's modified Eagle's medium; ECM = extracellular matrix; FBS = foetal bovine serum; GFP = green fluorescent protein; LPC = lateral posterior condyle; MFC = medial femoral condyle; OA = osteoarthritis.
###end p 60
###begin title 61
Competing interests
###end title 61
###begin p 62
The authors declare that they have no competing interests.
###end p 62
###begin title 63
Authors' contributions
###end title 63
###begin p 64
SRT conceived, designed and performed the experimental work associated with the microarray and was responsible for the initial versions of this manuscript. CJB collected the normal and OA cartilage and produced the cDNA libraries from femoral cartilage. CMR undertook the laboratory work associated with real time PCR analysis of the normal and OA cartilage libraries. PDC performed the statistical analyses, designed and validated the PCR primers, and supervised the project. TEH supervised and oversaw the completion of the studies as well as the writing of this manuscript. All authors read and approved the final manuscript.
###end p 64
###begin title 65
Acknowledgements
###end title 65
###begin p 66
###xml 129 134 <span type="species:ncbi:9606">Human</span>
The authors wish to thank Andrew Hayes and Leo Zeef for technical and analytical assistance with the microarray study and to the Human Genome Mapping Project for kindly providing the arrays. This work was funded by Biotechnology and Biological Sciences Research Council, Medical Research Council and Engineering and Physical Sciences Research Council, The Wellcome Trust (Research Leave Fellowship GR067462MA to PDC) and the Arthritis Research Campaign (Clinical Research Training Fellowship to CJB).
###end p 66
###begin article-title 67
Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis
###end article-title 67
###begin article-title 68
The impact of osteoarthritis: implications for research
###end article-title 68
###begin article-title 69
Molecular pathology and pathobiology of osteoarthritic cartilage
###end article-title 69
###begin article-title 70
SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes
###end article-title 70
###begin article-title 71
Late osteoarthritic cartilage shows down regulation of SOX9 and aggrecan expression but little evidence of chondrocyte hypertrophy
###end article-title 71
###begin article-title 72
SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6
###end article-title 72
###begin article-title 73
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human COL9A1 gene expression. Activation of the proximal promoter region by SOX9
###end article-title 73
###begin article-title 74
Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer
###end article-title 74
###begin article-title 75
###xml 62 67 <span type="species:ncbi:9606">human</span>
SOX9-dependent and -independent transcriptional regulation of human cartilage link protein
###end article-title 75
###begin article-title 76
Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9
###end article-title 76
###begin article-title 77
Sox9 is required for cartilage formation
###end article-title 77
###begin article-title 78
###xml 54 59 <span type="species:ncbi:9606">human</span>
Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors
###end article-title 78
###begin article-title 79
Tissue engineering: chondrocytes and cartilage
###end article-title 79
###begin article-title 80
###xml 16 21 <span type="species:ncbi:9606">human</span>
Transduction of human articular chondrocytes with adenoviral, retroviral and lentiviral vectors and the effects of enhanced expression of SOX9
###end article-title 80
###begin article-title 81
###xml 113 118 <span type="species:ncbi:9606">human</span>
Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes
###end article-title 81
###begin article-title 82
SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene
###end article-title 82
###begin article-title 83
Radiological assessment of osteo-arthrosis
###end article-title 83
###begin article-title 84
MAXD
###end article-title 84
###begin article-title 85
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation
###end article-title 85
###begin article-title 86
MIAMExpress
###end article-title 86
###begin article-title 87
Rapid isolation of total RNA from small samples of hypocellular, dense connective tissues
###end article-title 87
###begin article-title 88
Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes
###end article-title 88
###begin article-title 89
###xml 94 99 <span type="species:ncbi:9606">human</span>
Global cDNA amplification combined with real-time RT-PCR: accurate quantification of multiple human potassium channel genes at the single cell level
###end article-title 89
###begin article-title 90
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 90
###begin article-title 91
Vista browser
###end article-title 91
###begin article-title 92
rVista for comparative sequence-based discovery of functional transcription factor binding sites
###end article-title 92
###begin article-title 93
Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes
###end article-title 93
###begin article-title 94
The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage
###end article-title 94
###begin article-title 95
S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes
###end article-title 95
###begin article-title 96
###xml 118 123 <span type="species:ncbi:9606">human</span>
The differential effects of IL-1 and TNF-alpha on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells
###end article-title 96
###begin article-title 97
FGF signaling antagonizes cytokine-mediated repression of Sox9 in SW1353 chondrosarcoma cells
###end article-title 97
###begin article-title 98
Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9
###end article-title 98
###begin article-title 99
###xml 63 68 <span type="species:ncbi:9606">human</span>
Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta
###end article-title 99
###begin article-title 100
###xml 40 45 <span type="species:ncbi:9606">human</span>
A cholesteryl ester transfer complex in human plasma
###end article-title 100
###begin article-title 101
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human axillary odorant is carried by apolipoprotein D
###end article-title 101
###begin article-title 102
###xml 143 148 <span type="species:ncbi:9606">human</span>
Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts
###end article-title 102
###begin article-title 103
Repression of anti-proliferative factor Tob1 in osteoarthritic cartilage
###end article-title 103
###begin article-title 104
S100A1: a regulator of myocardial contractility
###end article-title 104
###begin article-title 105
###xml 71 79 <span type="species:ncbi:9606">patients</span>
A gene (SRPX) encoding a sushi-repeat-containing protein is deleted in patients with X-linked retinitis pigmentosa
###end article-title 105
###begin article-title 106
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Expression of Sox9 and type IIA procollagen during ocular development and aging in transgenic Del1 mice with a mutation in the type II collagen gene
###end article-title 106
###begin article-title 107
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Long-range activation of Sox9 in Odd Sex (Ods) mice
###end article-title 107
###begin article-title 108
CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
###end article-title 108
###begin article-title 109
Signaling pathways recruited by the cardiotrophin-like cytokine/cytokine-like factor-1 composite cytokine: specific requirement of the membrane-bound form of ciliary neurotrophic factor receptor alpha component
###end article-title 109

